MedPath

Optiscan doubles revenue, boosts profit for Sep qtr - Brisbane Times

Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Foresight Diagnostics Sets Strategic Goals for 2025 Following a Year of Significant Achievements

Foresight Diagnostics, a leader in minimal residual disease detection technology, has outlined its strategic goals for 2025, including expanding biopharma partnerships and preparing for the commercialization of its Foresight CLARITY™ technology. The company also reviewed its 2024 achievements, such as doubling its revenue, receiving FDA approval for its technology's use in a clinical trial, and advancing its position in the solid tumor MRD market.

Vergent Bioscience Completes Phase 2 Trial Enrollment of Abenacianine for Enhanced Lung Tumor Visualization

Vergent Bioscience has completed enrollment in its Phase 2 VISUALIZE trial evaluating abenacianine for injection (VGT-309) in lung cancer patients.
The trial assesses abenacianine's efficacy in improving the visibility of tumors during minimally invasive and robotic-assisted surgical procedures.

Aura Biosciences' Bel-sar Shows Promise in Choroidal Melanoma and Bladder Cancer Trials

Aura Biosciences reports positive Phase 2 data for bel-sar in early-stage choroidal melanoma, demonstrating 80% tumor control and 90% visual acuity preservation.
Phase 1 trial of bel-sar in NMIBC shows clinical complete response in low-grade disease and immune activation, suggesting potential as a novel immune-ablative treatment.

Perspective Therapeutics Advances Radiopharmaceutical Pipeline, Reports Promising Early Clinical Data

Perspective Therapeutics is progressing its lead asset \[212Pb\]VMT-α-NET in a Phase 1/2a trial for neuroendocrine tumors, with initial results presented at NANETS 2024.
The company's VMT01, targeting metastatic melanoma, shows encouraging safety and potential efficacy signals in early trials, leading to exploration of combination therapy with nivolumab.

Biofrontera's Ameluz Demonstrates Success in Phase III sBCC Trial, Stock Surges

Biofrontera's Ameluz-PDT therapy met the primary endpoint in a Phase III trial for superficial basal cell carcinoma (sBCC), showing significant clinical and histological clearance.
The Ameluz-PDT treatment achieved a 65.5% success rate compared to 4.8% in the placebo group, marking a substantial improvement in sBCC lesion clearance.

Vir Biotechnology Advances Oncology Pipeline with Dual-Masked T-Cell Engagers

Vir Biotechnology is advancing its oncology pipeline with three dual-masked T-cell engagers (TCEs) targeting HER2, PSMA, and EGFR.
Clinical data for VIR-5818 (HER2-targeted) and VIR-5500 (PSMA-targeted) are expected in Q1 2025, with Phase 1 studies ongoing.

FDA Accepts Telix Pharmaceuticals' Pixclara for Priority Review in Glioma Diagnosis

The FDA has accepted Telix Pharmaceuticals' New Drug Application for Pixclara, a diagnostic agent for gliomas, granting it priority review.
Pixclara aims to improve glioma diagnosis by overcoming limitations of conventional MRI, offering quicker and more reliable results.

Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA Phase III Trial for Prostate Cancer Receives Positive FDA Guidance

Clarity Pharmaceuticals' AMPLIFY trial, a Phase III study of 64Cu-SAR-bisPSMA for prostate cancer biochemical recurrence, received positive feedback from the FDA.
The AMPLIFY trial will enroll approximately 220 patients with rising PSA levels after initial prostate cancer treatment, with recruitment expected to begin in early 2025.

Vergent Bioscience Completes Enrollment in Phase 2 Trial of Abenacianine for Enhanced Tumor Visualization During Lung Cancer Surgery

Vergent Bioscience completed enrollment in its Phase 2 VISUALIZE trial evaluating abenacianine for injection (VGT-309) to improve tumor visualization during lung cancer surgery.
The trial enrolled 89 patients with lung cancer across six sites in the US and Australia, each receiving 0.32mg/kg of abenacianine prior to surgery.

Innovations and Trials in Medical Technology

Recent advancements in medical technology include the launch of the CrossWise RF transseptal access system by Circa Scientific, completion of enrollment in a pivotal trial for Inquis Medical's Aventus thrombectomy system, a distribution agreement between Medtronic and Contego Medical, a $12 million Series A round for Relief Cardiovascular, CE mark approval for Johnson & Johnson MedTech's dual-energy catheter, a temporary pause on Varipulse PFA system cases by Johnson & Johnson MedTech, and the completion of a first-in-human study by AerWave for its lung denervation therapy.

Reference News

[1]
Optiscan doubles revenue, boosts profit for Sep qtr - Brisbane Times
brisbanetimes.com.au · Oct 31, 2024

Optiscan's CEO, Dr. Camile Farah, highlights significant progress in clinical studies and R&D, including a soon-to-be-re...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy